Singapore
Engine Biosciences, founded in 2014, stands at the intersection of biotechnology and artificial intelligence, revolutionizing the drug discovery landscape. Headquartered in Singapore and maintaining significant operations in San Francisco and Asia, this innovative tech company specializes in network biomedicine. By leveraging both high-throughput wet lab experimentation and advanced AI algorithms, Engine Biosciences has developed a proprietary platform aimed at reducing the time and cost associated with R&D for medical therapies.
The company's strategic focus on deciphering biological complexity aligns with its mission to create impactful medicines. With a substantial $10M seed round secured in January 2018 and a recent $27.00M Series A investment concluded on 31 October 2023, Engine Biosciences has attracted investments from prominent players like EDBI, Polaris Partners, and Invus. This financial backing underscores confidence in the company's scientific expertise and disruptive potential in healthcare.
